REG - Malin Corp PLC - Holding(s) in Company

MalinAnnouncement

11/04/2019 18:35

RNS Number : 9677V
Malin Corporation PLC
11 April 2019
 


 
Malin Corporation plc
('Malin' or 'the Company')
 
Holding(s) in Company
 
Malin received notification on 11 April, 2019 from Aviva Investors Global Services Limited that as of 10 April, 2019 it holds an aggregate interest in 2,255,045 ordinary shares of €0.001 each, which represents 4.94%* of the issued share capital of the Company. 
 
*This percentage shareholding is based on a shares in issue figure of 45,681,093 ordinary shares.
 
Contacts:
 
Malin
Susan Holburn, Company Secretary
Tel: +353 (0)1 901 5700
info@malinplc.com
 
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
 
Powerscourt (Irish media enquiries)              
Eavan Gannon                                              
Tel: +353 87 236 5973                            
malin@powerscourt-group.com                                                                          
 
Davy Corporate Finance (Euronext Growth Advisor)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
 
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLQFLFFKZFFBBD